

For Immediate Release



## Renowned leader in the anti-infective drug industry invests in ANTABIO

Labège, France, January 12, 2012. ANTABIO, the biopharmaceutical antibacterial drug discovery company, welcomes M. Christophe RICARD former CEO of the Swiss pharmaceutical group OM Pharma as its new investor. Under Mr RICARD's leadership, OM Pharma developed and commercialized two record selling drugs aimed at preventing and treating bacterial infections, Broncho-Vaxom® and Uro-Vaxom®, prior to being acquired by the Galenica group in 2009. As a new investor Christophe RICARD will provide ANTABIO with significant industrial expertise in the infectious disease space.

"I have always been convinced that one of the main health challenges of the 21st century resides in providing background therapies against recurrent infections and in addressing antibiotic resistance" says Christophe Ricard. "I am excited to become a shareholder of ANTABIO, a company which novel and complementary discovery programs and strong management team is in a good position to deliver solutions to these problems in the medium-term."

«The arrival of Mr RICARD among ANTABIO's shareholders is a token of credibility and recognition to our strategy to develop novel treatments against antibiotic-resistant infections » says Marc LEMONNIER, CEO of ANTABIO. « This novel fundraising gives us the financial means to achieve our immediate R&D objectives allowing us to reach our next 2012 milestones. Antabio is seeking additional investment to further its programs while considering developing partnerships with strategic pharma and biotech companies. We are pursuing our discussions with professional investors in order to complete the 5M€ fundraising that will take us to the first trials of our first-in-class molecules in man by the end of 2014".

**About ANTABIO:** ANTABIO is a Toulouse, France-based start-up biopharmaceutical company dedicated to the discovery of novel drugs to treat and prevent antibiotic-resistant bacterial infections. Based on its patented technology and unique know-how, ANTABIO develops first-in-class small molecule compounds that will offer a synergistic solution to the shortfall of antibiotics to treat severe nosocomial infections as well as community-acquired conditions like urinary tract infections. The company is currently engaged in developing novel anti-resistance compounds that will partner antibiotics for them to regain their activity against multi- or pan-drug resistant Gram-negative pathogens such as *Escherichia coli* (*E. coli*) NDM-1 bacteria. ANTABIO also owns a proprietary antivirulence technology to characterize compounds that can treat and prevent infections caused by virulent and multi-drug resistant bacteria. [www.antabio.com](http://www.antabio.com)

### Press Contact:

#### ANTABIO

M. Marc LEMONNIER

Tel. + 33 5 61 28 70 32

[info@antabio.com](mailto:info@antabio.com)